e-learning
resources
Berlin 2008
Sunday, 05.10.2008
Pulmonary vascular disease and other pulmonary conditions: miscellaneous
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Combination therapy with sildenafil and sitaxentan therapy for pulmonary arterial hypertension
R. Voswinckel, N. Gross, F. Reichenberger, M. Thamm, B. Karadas, H. Gall, H. Nef, F. Grimminger, W. Seeger, H. A. Ghofrani (Giessen, Germany)
Source:
Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous
Session:
Pulmonary vascular disease and other pulmonary conditions: miscellaneous
Session type:
Thematic Poster Session
Number:
1078
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Voswinckel, N. Gross, F. Reichenberger, M. Thamm, B. Karadas, H. Gall, H. Nef, F. Grimminger, W. Seeger, H. A. Ghofrani (Giessen, Germany). Combination therapy with sildenafil and sitaxentan therapy for pulmonary arterial hypertension. Eur Respir J 2008; 32: Suppl. 52, 1078
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension
Source: Eur Respir J, 56 (3) 2000673; 10.1183/13993003.00673-2020
Year: 2020
Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension
Source: Annual Congress 2009 - Pulmonary arterial hypertension
Year: 2009
Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension
Source: Eur Respir J 2015; 46: 405-413
Year: 2015
Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension
Source: Eur Respir J 2007; 29: 469-475
Year: 2007
Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Long-term treatment of pulmonary hypertension with aerosolized iloprost
Source: Eur Respir J 2001; 17: 8-13
Year: 2001
Differential response to the addition of sildenafil to bosentan monotherapy between idiopathic and scleroderma-associated pulmonary arterial hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 547s
Year: 2006
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2
Source: Eur Respir J 2004; 24: 353-359
Year: 2004
Initial dual oral combination therapy in pulmonary arterial hypertension
Source: Eur Respir J 2016; 47:1727-1736
Year: 2016
Dipyridamol as adjuvant therapy in patients with pulmonary arterial hypertension (PAH)
Source: Eur Respir J 2005; 26: Suppl. 49, 562s
Year: 2005
Clinical efficacy of oral sildenafil therapy in the treatment of pulmonary hypertension
Source: Eur Respir J 2007; 30: Suppl. 51, 347s
Year: 2007
Patterns of therapy with sildenafil among patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010
Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights
Source: Eur Respir J 2015; 46: 414-421
Year: 2015
Response to exercise in patients with pulmonary arterial hypertension treated with combination therapy
Source: ERJ Open Res, 7 (1) 00725-2020; 10.1183/23120541.00725-2020
Year: 2021
Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy
Source: Eur Respir J 2005; 26: Suppl. 49, 476s
Year: 2005
Combination therapy in severe pulmonary hypertension with bosentan and treprostinil: successful switch from subcutaneous to intravenous application
Source: Eur Respir J 2006; 28: Suppl. 50, 384s
Year: 2006
Low dose intravenous iloprost therapy in idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 426s
Year: 2006
Safety and efficacy of bosentan in combination with sildenafil in pulmonary arterial hypertension: The COMPASS-3 study
Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models
Year: 2011
Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015
Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension
Source: Eur Respir J, 57 (1) 2001120; 10.1183/13993003.01120-2020
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept